570 related articles for article (PubMed ID: 29325685)
1. Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone.
Miura Y; Saito T; Tanaka T; Takoi H; Yatagai Y; Inomata M; Nei T; Saito Y; Gemma A; Azuma A
Respir Investig; 2018 Jan; 56(1):72-79. PubMed ID: 29325685
[TBL] [Abstract][Full Text] [Related]
2. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
Ikeda K; Shiratori M; Chiba H; Nishikiori H; Yokoo K; Saito A; Hasegawa Y; Kuronuma K; Otsuka M; Yamada G; Takahashi H
Respir Med; 2017 Oct; 131():184-191. PubMed ID: 28947028
[TBL] [Abstract][Full Text] [Related]
3. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
4. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.
Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U
Respiration; 2017; 93(6):415-423. PubMed ID: 28399537
[TBL] [Abstract][Full Text] [Related]
5. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis.
Arai T; Inoue Y; Sasaki Y; Tachibana K; Nakao K; Sugimoto C; Okuma T; Akira M; Kitaichi M; Hayashi S
Respir Investig; 2014 Mar; 52(2):136-43. PubMed ID: 24636270
[TBL] [Abstract][Full Text] [Related]
6. Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis.
Iwata T; Yoshida S; Fujiwara T; Wada H; Nakajima T; Suzuki H; Yoshino I
Ann Thorac Surg; 2016 Dec; 102(6):1905-1910. PubMed ID: 27546601
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.
Tzouvelekis A; Ntolios P; Karampitsakos T; Tzilas V; Anevlavis S; Bouros E; Steiropoulos P; Koulouris N; Stratakos G; Froudarakis M; Bouros D
Pulm Pharmacol Ther; 2017 Oct; 46():48-53. PubMed ID: 28843616
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).
Iwata T; Yoshino I; Yoshida S; Ikeda N; Tsuboi M; Asato Y; Katakami N; Sakamoto K; Yamashita Y; Okami J; Mitsudomi T; Yamashita M; Yokouchi H; Okubo K; Okada M; Takenoyama M; Chida M; Tomii K; Matsuura M; Azuma A; Iwasawa T; Kuwano K; Sakai S; Hiroshima K; Fukuoka J; Yoshimura K; Tada H; Nakagawa K; Nakanishi Y;
Respir Res; 2016 Jul; 17(1):90. PubMed ID: 27450274
[TBL] [Abstract][Full Text] [Related]
9. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.
Taguchi Y; Ebina M; Hashimoto S; Ogura T; Azuma A; Taniguchi H; Kondoh Y; Suga M; Takahashi H; Nakata K; Sugiyama Y; Kudoh S; Nukiwa T;
Respir Investig; 2015 Nov; 53(6):279-87. PubMed ID: 26521105
[TBL] [Abstract][Full Text] [Related]
11. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Nathan SD; Costabel U; Albera C; Behr J; Wuyts WA; Kirchgaessler KU; Stauffer JL; Morgenthien E; Chou W; Limb SL; Noble PW
Respir Med; 2019 Jul; 153():44-51. PubMed ID: 31153107
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis--Extended analysis of pirfenidone trial in Japan.
Kondoh Y; Taniguchi H; Ebina M; Azuma A; Ogura T; Taguchi Y; Suga M; Takahashi H; Nakata K; Sugiyama Y; Kudoh S; Nukiwa T
Respir Investig; 2015 Nov; 53(6):271-8. PubMed ID: 26521104
[TBL] [Abstract][Full Text] [Related]
13. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
14. All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis.
Ogura T; Azuma A; Inoue Y; Taniguchi H; Chida K; Bando M; Niimi Y; Kakutani S; Suga M; Sugiyama Y; Kudoh S; Nukiwa T
Respir Investig; 2015 Sep; 53(5):232-41. PubMed ID: 26344613
[TBL] [Abstract][Full Text] [Related]
15. Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis.
Iwata T; Yoshida S; Nagato K; Nakajima T; Suzuki H; Tagawa T; Mizobuchi T; Ota S; Nakatani Y; Yoshino I
Surg Today; 2015 Oct; 45(10):1263-70. PubMed ID: 25412984
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study.
Harari S; Caminati A; Albera C; Vancheri C; Poletti V; Pesci A; Luppi F; Saltini C; Agostini C; Bargagli E; Sebastiani A; Sanduzzi A; Giunta V; Della Porta R; Bandelli GP; Puglisi S; Tomassetti S; Biffi A; Cerri S; Mari A; Cinetto F; Tirelli F; Farinelli G; Bocchino M; Specchia C; Confalonieri M
Respir Med; 2015 Jul; 109(7):904-13. PubMed ID: 25962649
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
Okuda R; Hagiwara E; Baba T; Kitamura H; Kato T; Ogura T
Respir Med; 2013 Sep; 107(9):1431-7. PubMed ID: 23849626
[TBL] [Abstract][Full Text] [Related]
18. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
[TBL] [Abstract][Full Text] [Related]
19. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.
Costabel U; Albera C; Bradford WZ; Hormel P; King TE; Noble PW; Sahn SA; Valeyre D; du Bois RM
Sarcoidosis Vasc Diffuse Lung Dis; 2014 Oct; 31(3):198-205. PubMed ID: 25363219
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis.
Ren H; Wang K; Yang H; Gao L
Saudi Med J; 2017 Sep; 38(9):889-894. PubMed ID: 28889145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
